Market access has become a focus for nearly every multinational pharmaceutical, medical device, and diagnostics company. In recent years, some have even created a functional executive to drive market access initiatives both internally and externally. While the growing importance of market access is widely recognized, there is no consensus on a specific definition, the best approach to it, or who should lead the effort.
The simplest definition goes something like this: getting the right treatment to the right patient at the right time, including, of course, timely reimbursement at margin-producing levels. However, in emerging markets—where multinational healthcare firms are increasingly turning for growth—this description fails to capture the complexity involved in achieving this goal.
Our latest white paper provides a market access framework to help you develop a corporate approach to the challenge, with inputs from country teams and local partners to localize the strategy as much as possible.
Please fill out the form below to download this white paper.